Implementation Brief: Considerations for developers in applying the Multiple Best Price (MBP) rule to improve access to novel therapies

Eric NormanFoCUS, Research Briefs

Thumbnail picture of the implementation brief

This brief highlights some key steps and considerations for biopharmaceutical developers of novel, high-value therapies seeking to successfully implement CMS’s Multiple Best Price rule. The rule, which went into effect in 2022, addresses the challenge of establishing a Medicaid best price under a Value-Based Contract.

NEWDIGS Innovation Brief MBP Considerations (PDF)

Share the research